Merz's Novabel Suspended In EU, Pausing New Business Strategy As Well
This article was originally published in The Pink Sheet Daily
Executive Summary
Reports of skin nodules bring temporary halt to marketing of the dermal filler, which Merz was relying on to attain a leadership position in aesthetic medicine.
You may also be interested in...
Merz Pharma Gains Radiesse Dermal Filler Via $253 Mil. BioForm Acquisition
Merz Pharma Group will round out its aesthetic product offerings by adding the Radiesse wrinkle filler device through its $253 million acquisition of BioForm Medical, announced Jan. 4
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.